Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Kenneth,Emancipator

第一单位： Companion Diagnostics, Merck & Co., Inc., Kenilworth, NJ, USA. kenneth.emancipator@merck.com.

作者： Kenneth,Emancipator ^[1] ; Lingkang,Huang ^[2] ; Deepti,Aurora-Garg ^[3] ; Tricia,Bal ^[4] ; Ezra E W,Cohen ^[5] ; Kevin,Harrington ^[6] ; Denis,Soulières ^[7] ; Christophe,Le Tourneau ^[8] ; Lisa,Licitra ^[9] ; Barbara,Burtness ^[10] ; Ramona,Swaby ^[11]

作者单位： Companion Diagnostics, Merck & Co., Inc., Kenilworth, NJ, USA. kenneth.emancipator@merck.com. ^[1] Health Economics and Outcomes Research, Merck & Co., Inc., Kenilworth, NJ, USA. ^[2] Companion Diagnostics, Merck & Co., Inc., Kenilworth, NJ, USA. ^[3] Biomarkers and Diagnostics, Merck & Co., Inc., Kenilworth, NJ, USA. ^[4] Translational Science, Moores Cancer Center, UC San Diego Health, La Jolla, CA, USA. ^[5] Division of Radio Therapy and Imaging, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, UK. ^[6] Hematology & Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. ^[7] Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, INSERM U900 Research Unit, Saint-Cloud, Paris-Saclay University, Paris, France. ^[8] Head and Neck Cancer, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy. ^[9] Medical Oncology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. ^[10] Late-Stage Immuno-Oncology Research and Development, Merck & Co., Inc., Kenilworth, NJ, USA. ^[11]